Australia's largest stock trading and investment forum Australia's #1 stock forum

VHT volpara health technologies limited

0.00%

$1.15

Long Term Bullish - Short Term Not, page-4

First 4 Last

Share
Profile

Follow
LongTony

2,966 Posts.

2625

17/10/19

02:44

Post #: 40920971
Share

Originally posted by jellyroll: ↑

Seems like some people on the board are bulled up in the extreme and in the longer term you will be right .... I suspect that in the shorter term (next 6 to 12 months) some of the more bullish forecasts are going to be very hard to be meet.

1) This quarter just closed is historically their weakest quarter by far.
2) This was also the quarter last year when they pulled down their sales forecasts for 2019.
3) If you back out the "market share" bought from MRS then their market share of the underlying Volpara suite is forecast at the end of this year to be where they were forecasting it would be at the end of last year.
4) They have never broken out how they are selling by manufacturer .... anecdotally to date they do very well with GE and not well with Hologic - For those that don't know Hologic is well over 50% of the US market for mammogram machines. Hologic has its own density product called Quanta and while inferior it would seem it makes sales on these machines more much difficult to close.
5) Selling the extra services and properly pricing density is slow work, not helped by the longer-term (now all 5 year) contracts they are entering in to.
6) They are having to customize their product for the larger networks who are also requiring trials .... they will get there but it moves very very slowly.

In summary, I think you will find that sales will happen and that they will be sticky but that sales conversion and price increase are going to be materially slower than some of the predictions I have read on the board recently. Add any potential disappointment this may cause and possible market turbulence over the next 6 to 12 months and I think you may get the opportunity to top up at a price not far above $1. As a reminder on the valuation side Morgans don't have VHT making a profit until FY2022 and then it is 7 cents. That puts Volpara on 23x FY 2022. If we take the average of all 3 analyst that cover the stock it is on 37x FY 2022. A great business and but it is going to require some patience and a strong stomach for volatility. On the plus side I am very keen to see them move in to the clinical trials space I think there is quick and material upside to revenue from that move, also I am keen to see what they can do in lung and what level of investment a density/enterprise product in that space would require. Management team is very strong and capable but they are going to need to be given time.

Expand

I'm calling shenanigans on you, jellyroll

If you wanted to sell you had plenty of chance on today's run up. In response:
1. great for YoY comparison
2. same
3. therefore easy to hit
4. implication-free-zone
5. selling well with extra services to roll in, slow but as you say in your summary profit is here the year after next and growing strongly. After that, it's locked in on 5-year contracts (how good is that?!)
6. love locking in large networks

As you say in closing, management is strong; and reputable investors with a good track record say that backing the team is good advice for making money

VHT Price at posting: $1.63 Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

AIV

ActivEX Monday's top gainer at lunchtime as maiden JORC spurs surge

STX

Monday's HotCopper Trends: Strike Energy pause, Anteotech's US team-up | July 21

PTX

This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

PSC

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

First 4 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.